{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:23:13Z","timestamp":1792596193042,"version":"4.5.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,8]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Venetoclax demonstrates potent in vitro and in vivo single-agent activity in MLL-rearranged ALL xenografts. Clinically efficacious BH3-mimetic therapy for other high-risk ALL subtypes is likely to require concurrent BCL-2 and BCL-XL inhibition.<\/jats:p>","DOI":"10.1182\/blood-2016-03-707414","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T22:28:30Z","timestamp":1466807310000},"page":"1382-1395","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":166,"title":["Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-8974","authenticated-orcid":false,"given":"Seong Lin","family":"Khaw","sequence":"first","affiliation":[{"name":"Walter Eliza Hall Institute of Medical Research, Melbourne, Australia;"},{"name":"Royal Children\u2019s Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santi","family":"Suryani","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Evans","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Richmond","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Robbins","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raushan T.","family":"Kurmasheva","sequence":"additional","affiliation":[{"name":"Greehey Children\u2019s Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Billups","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Research Triangle Institute International, Research Triangle Park, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelong","family":"Guo","sequence":"additional","affiliation":[{"name":"Research Triangle Institute International, Research Triangle Park, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Houghton","sequence":"additional","affiliation":[{"name":"Greehey Children\u2019s Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Carol","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Walter Eliza Hall Institute of Medical Research, Melbourne, Australia;"},{"name":"Faculty of Medicine, Dental and Health Sciences, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"Walter Eliza Hall Institute of Medical Research, Melbourne, Australia;"},{"name":"Faculty of Medicine, Dental and Health Sciences, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lock","sequence":"additional","affiliation":[{"name":"Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2019111908452906000_B1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality.","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2019111908452906000_B2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children\u2019s Cancer Group (CCG).","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111908452906000_B3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1998.16.2.527","article-title":"Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children\u2019s Cancer Group.","volume":"16","author":"Uckun","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111908452906000_B4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","article-title":"Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.","volume":"110","author":"Nachman","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2019111908452906000_B5","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.","volume":"122","author":"van der Veer","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111908452906000_B6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.leu.2402883","article-title":"Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.","volume":"17","author":"Pui","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2019111908452906000_B7","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study.","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2019111908452906000_B8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy.","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"issue":"5647","key":"2019111908452906000_B9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1090072","article-title":"p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.","volume":"302","author":"Villunger","year":"2003","journal-title":"Science"},{"issue":"4","key":"2019111908452906000_B10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111908452906000_B11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V97.2.572","article-title":"Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse.","volume":"97","author":"Carter","year":"2001","journal-title":"Blood"},{"key":"2019111908452906000_B12","author":"Bhojwani"},{"issue":"10","key":"2019111908452906000_B13","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.leu.2401529","article-title":"Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.","volume":"13","author":"Salomons","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"2019111908452906000_B14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140","article-title":"Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.","volume":"87","author":"Coustan-Smith","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111908452906000_B15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2009-02-205963","article-title":"Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.","volume":"115","author":"Stam","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111908452906000_B16","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2004-05-2023","article-title":"Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.","volume":"105","author":"Bachmann","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2019111908452906000_B17","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/blood-2010-05-284968","article-title":"Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.","volume":"116","author":"Bachmann","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111908452906000_B18","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-13-1215","article-title":"Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.","volume":"19","author":"Gagn\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111908452906000_B19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"2019111908452906000_B20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111908452906000_B21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span.","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"2","key":"2019111908452906000_B22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"25","key":"2019111908452906000_B23","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111908452906000_B24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"7042","key":"2019111908452906000_B25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours.","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"6","key":"2019111908452906000_B26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2019111908452906000_B27","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111908452906000_B28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.","volume":"77","author":"High","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2019111908452906000_B29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2004.05155.x","article-title":"Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors.","volume":"127","author":"Hartung","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111908452906000_B30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.leu.2403231","article-title":"Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.","volume":"18","author":"Menendez","year":"2004","journal-title":"Leukemia"},{"issue":"11","key":"2019111908452906000_B31","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"2019111908452906000_B32","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2003-08-2911","article-title":"Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.","volume":"103","author":"Liem","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111908452906000_B33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1535-7163.MCT-14-0647","article-title":"Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.","volume":"14","author":"Suryani","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111908452906000_B34","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","article-title":"The pediatric preclinical testing program: description of models and early testing results.","volume":"49","author":"Houghton","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2019111908452906000_B35","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/0008-5472.CAN-06-4244","article-title":"Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.","volume":"67","author":"Bachmann","year":"2007","journal-title":"Cancer Res"},{"key":"2019111908452906000_B36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/1471-2164-12-565","article-title":"Evaluation of the NOD\/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia.","volume":"12","author":"Bhadri","year":"2011","journal-title":"BMC Genomics"},{"issue":"1","key":"2019111908452906000_B37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Statist Soc B"},{"key":"2019111908452906000_B38","doi-asserted-by":"crossref","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments.","author":"Smyth","DOI":"10.2202\/1544-6115.1027"},{"key":"2019111908452906000_B39","author":"Baell"},{"issue":"279","key":"2019111908452906000_B40","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"3","key":"2019111908452906000_B41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly.","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"13","key":"2019111908452906000_B42","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.","volume":"112","author":"Hallaert","year":"2008","journal-title":"Blood"},{"key":"2019111908452906000_B43","author":"DeAngelo"},{"issue":"7","key":"2019111908452906000_B44","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2.","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"19 Suppl","key":"2019111908452906000_B45","article-title":"Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL) [abstract].","volume":"74","author":"Wayne","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"2019111908452906000_B46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111908452906000_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2292.2292","article-title":"Phase 1\/2 study in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment [abstract].","volume":"124","author":"von Stackelberg","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111908452906000_B48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"303","key":"2019111908452906000_B49","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"26","key":"2019111908452906000_B50","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"9747","key":"2019111908452906000_B51","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2019111908452906000_B52","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/gcc.22163","article-title":"Acute lymphoblastic leukemia with low hypodiploid\/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.","volume":"53","author":"M\u00fchlbacher","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111908452906000_B53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"issue":"5203","key":"2019111908452906000_B54","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.7878471","article-title":"Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice.","volume":"267","author":"Motoyama","year":"1995","journal-title":"Science"},{"issue":"2","key":"2019111908452906000_B55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.183.2.381","article-title":"bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice.","volume":"183","author":"Grillot","year":"1996","journal-title":"J Exp Med"},{"issue":"2","key":"2019111908452906000_B56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(93)80065-M","article-title":"Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair.","volume":"75","author":"Veis","year":"1993","journal-title":"Cell"},{"issue":"6","key":"2019111908452906000_B57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111908452906000_B58","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 vs BCL-XL dependence and sensitivity to ABT-199.","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"25","key":"2019111908452906000_B59","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111908452906000_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.327.327","article-title":"A phase 1b study of venetoclax (ABT-199\/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are \u2265 to 65 years and not eligible for standard induction therapy [abstract].","volume":"126","author":"DiNardo","year":"2015","journal-title":"Blood"},{"issue":"9583","key":"2019111908452906000_B61","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"2019111908452906000_B62","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Reports"},{"issue":"9","key":"2019111908452906000_B63","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.","volume":"47","author":"Fisher","year":"2015","journal-title":"Nat Genet"},{"issue":"24","key":"2019111908452906000_B64","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","article-title":"Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.","volume":"119","author":"M\u00e9rino","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1382\/1395001\/1382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1382\/1395001\/1382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T17:56:29Z","timestamp":1718646989000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/10\/1382\/35312\/Venetoclax-responses-of-pediatric-ALL-xenografts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-707414","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726465378.793525471","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}